The biological processes giving rise to the central nervous system symptoms of long COVID remain a mystery. But multiple studies suggest they do not appear to be a result of a direct viral infection of brain tissue. The latest such research, which appeared online in Nature Neuroscience on Feb. 16, 2024, demonstrated that local immune response in brain tissues persisted long after SARS-CoV-2 virus had disappeared. Read More
In a recent study, researchers from Technische Universität Dresden and affiliated organizations evaluated the novel small-molecule inhibitor of the CBP/p300 HAT domain, A-485, as a potential therapeutic candidate for the treatment of hematological cancers and other pathologies related to blood leukocyte compartment. Read More
Vidac Pharma Holdings plc has released promising results for VDA-1275 in mouse cancer and human cellular organoid models of solid tumors, with VDA-1275 showing efficacy as a monotherapy and synergistic effects in combination with sorafenib and cisplatin. Read More
Researchers at the University of Ottawa have reported on the use of vanoxerine as a suppressor of CSC tumorigenic activity in preclinical models of colorectal cancer. Read More
The company has developed a method of transplantation of human hematopoietic stem cells that allows their engraftment and differentiation into microglial cells.
Read More
Because selective BET inhibitors present better efficacy and safety than pan-BET inhibitors, current research is focused on the development of BD1- or BD2-selective inhibitors. Read More
A Sanofi SA patent describes imidazopyridine compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors and reported to be useful for the treatment of cancer. Read More
Imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators have been described in a UCB SA patent and are reported to be potentially useful for the treatment of inflammatory disorders and autoimmune diseases. Read More
Pompe disease is a disorder caused by deficiency of the lysosomal acid α-glucosidase (GAA) enzyme, which leads to the accumulation of glycogen within the lysosomes, overall in skeletal and cardiac muscle. Read More
Anadolu University and Atatürk University have jointly described novel 3,5-disubstituted-1,2,4-oxadiazole derived compounds acting as carbonic anhydrase type I and/or type II inhibitors. Read More
Almirall S.A. has entered into an exclusive license agreement with Novo Nordisk A/S for global rights to develop and commercialize the IL-21-blocking monoclonal antibody NN-8828 in certain fields, including immune inflammatory dermatological diseases. Read More
